White House sources indicate Trump approved Makary’s removal, reflecting escalating senior leadership churn across federal health agencies. Makary’s tenure featured MAHA-aligned regulatory positions, ...
In today's Pharmaceutical Executive Daily, Angelini Pharma announces a $4.1 billion agreement to acquire Catalyst ...
Madrigal Pharmaceuticals entered an exclusive global license agreement with Arrowhead Pharmaceuticals for ARO-PNPLA3, a ...
Consideration is set at $31.50 per Catalyst share in cash, implying an equity value above $4.1 billion and a 21% premium to ...
Pharmaceutical Executive: What elements is the conversation about bringing pharma manufacturing home missing? Charlie Lyon: ...
In March of this year, the API Innovation Center released its whitepaper titled, “From Fragility to Resilience: Aligning ...
Natalie de Graaf is VP and GM of Data, AI and ML; Solutions for Health and National Security at the API Innovation Center. Natalie de Graaf, from the API Innovation Center, discusses a recent ...
In today's Pharmaceutical Executive Daily, Cellenkos announces FDA clearance of its investigational new drug application for ...
UCB enters agreement to acquire Candid Therapeutics in a deal worth up to $2.2 billion, adding BCMA-targeting T-cell engager ...
FDA cleared the first agent with an NMDA/sigma-1–based mechanism specifically for agitation in Alzheimer’s disease dementia, ...
There are two main changes required to break the operational cost barrier. The first is technology-enabled automation. By ...
FDA authorization supports a mid-stage clinical evaluation of CK0802 in steroid-refractory GVHD, where steroid nonresponse is ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results